Skip to main content

Understanding compound selectivity with data-driven drug design

Selectivity is a crucial property in the development of new active pharmaceutical ingredients (APIs). Binding site comparisons within a protein family are key to modulating the selectivity profile of a potential new API, which includes understanding both on- and off-target effects. This white paper outlines the importance of data-driven-drug design to maximise compound selectivity.

Premium Access

To access this content please enter your details in the fields below.

Media Partners